← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2010Last known activity
Sep 5, 2025
Timeline
2000s
- Jun 1, 2009
Apices Soluciones S.L.— Founded
Drugs by trial phase (64 distinct, 32 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (16 own, 0 via acquisition)
Phase 2 (44 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Colorectal Neoplasms
- Coronavirus Infections
- Head and Neck Neoplasms
- Kidney Neoplasms
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Neoplasm Metastasis
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Respiratory Insufficiency
- Severe Acute Respiratory Syndrome
- Squamous Cell Carcinoma of Head and Neck
- Triple Negative Breast Neoplasms
- Urinary Bladder Neoplasms
- Uterine Cervical Neoplasms
Recent trials (32)
- NCT07029737CollaboratorPhase 2Sep 5, 2025
- NCT06892054CollaboratorPhase 2Jun 30, 2025
- NCT06764186CollaboratorPhase 3Jan 7, 2025
- NCT06746116CollaboratorPhase 3Dec 31, 2024
- NCT06133517CollaboratorPhase 2Mar 31, 2024
- NCT05121740CollaboratorPhase 1/Phase 2Dec 13, 2021
- NCT04827953CollaboratorPhase 1/Phase 2Sep 1, 2021
- NCT04758533CollaboratorPhase 1/Phase 2Apr 19, 2021
- NCT04483505CollaboratorPhase 1Nov 25, 2020
- NCT04494958CollaboratorPhase 1/Phase 2Nov 18, 2020
- NCT04382066CollaboratorPhase 1May 12, 2020
- NCT04366271CollaboratorPhase 2May 7, 2020
- NCT04316182CollaboratorPhase 2Apr 30, 2020
- NCT04348695CollaboratorPhase 2Apr 12, 2020
- NCT04282109CollaboratorPhase 2Mar 31, 2020
Details
- Founded
- Madrid, ES Jun 1, 2009
- Last known activity
- Sep 5, 2025
Notes
CRO